FDA expands Jaypirca to first‑line CLL/SLL treatment
The U.S. Food and Drug Administration approved Eli Lilly’s oral BTK inhibitor Jaypirca for use as an initial therapy in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who lack a 17p deletion. The decision follows a phase‑III trial of 282 participants that demonstrated an 80% lower risk of disease progression or death versus chemo‑immunotherapy. The label extension adds a new patient pool to the drug’s existing indications for relapsed or refractory disease.
Why it matters
Lilly expects the broader indication to increase Jaypirca’s market reach, potentially boosting future sales beyond the $357 million recorded in the first half of 2026, which already reflected a 66% year‑over‑year rise. The expanded use may also improve the company’s oncology revenue share relative to its larger obesity and diabetes businesses.
Key facts
- 1The FDA approved Jaypirca for first‑line treatment of CLL/SLL in patients without a known 17p deletion. intellectia.ai
- 2The supporting phase‑III BRUIN CLL‑313 trial enrolled 282 patients. intellectia.ai
- 3The trial showed an 80% reduction in risk of disease progression or death compared with chemo‑immunotherapy. theglobeandmail.com
- 4Jaypirca generated $357 million in revenue in the first half of 2026. theglobeandmail.com
- 5Revenue in that period was up 66% year over year. theglobeandmail.com
Summary written by AlphAI from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.